drugset / Trial / NCT00405561
Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate efficacy and safety of AMT2003 in cancer patients with advanced colorectal carcinoma. The primary endpoint is progression free survival rate at 18 weeks after registration
Timeline
- Start
- 2006-10
- Primary completion
- 2010-01
- Completion
- 2010-01
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMT2003 | Unknown | — | — |